Inside the FDA's March 2026 Warning Letters to 30 Compounded GLP-1 Telehealth Companies

On March 3, 2026, the FDA issued 30 warning letters to compounded GLP-1 telehealth operators. Inside the filings: what was alleged, who responded, and what it means for patients.

On March 3, 2026, the U.S. Food and Drug Administration issued 30 warning letters to telehealth companies and compounding pharmacies marketing compounded GLP-1 medications. It was the largest single-day enforcement action the agency has ever taken in the telehealth compounding space, and it marked a clear end to the post-shortage grace period that many operators had been counting on.

The letters targeted companies for a range of alleged violations: marketing compounded semaglutide and tirzepatide as FDA-approved, making unproven safety and efficacy claims, selling oral or sublingual formulations that were never part of the original shortage-era compounding allowance, and continuing to mass-produce medications after the FDA had declared the underlying shortages resolved.

What the Letters Actually Allege

The warning letters fall into roughly three categories. The first targets companies that kept marketing compounded GLP-1s using language that implied FDA approval — phrases like "FDA-cleared," "pharmacy-grade," or comparisons that suggested equivalence to Wegovy, Ozempic, or Zepbound without the required disclaimers. Under FDA compounding rules, compounded drugs are not FDA-approved and cannot be marketed as such.

The second category addresses novel formulations. Several companies had been selling oral, sublingual, and nasal-spray versions of semaglutide and tirzepatide — routes of administration that have never been studied in pivotal trials and were never contemplated by the shortage-era 503A and 503B compounding rules. The FDA explicitly called these out as outside the scope of permissible compounding.

The third category is about shortage status. Semaglutide was removed from the FDA shortage list in February 2025, and tirzepatide was removed in December 2024. Under federal law, 503B outsourcing facilities can only produce essentially-copy versions of commercially-available drugs while those drugs are in shortage. Several letters flagged continued large-volume production months after the shortages were officially resolved.

Who Received Letters and Who Didn't

The FDA did not publish the full list of recipients as a single disclosure, but individual letters have been posted on the agency's warning letters database. The named entities include a mix of direct-to-consumer telehealth brands, the compounding pharmacies fulfilling their prescriptions, and a handful of marketing entities that don't prescribe or dispense but drive traffic to those that do.

Notably, several large telehealth brands that had already pivoted to brand-name distribution partnerships with Novo Nordisk and Eli Lilly were not on the March 3 list. That is not a coincidence. Companies that have moved to prescribing FDA-approved Wegovy or Zepbound through authorized channels are operating inside the regulatory lane the FDA wants the industry in.

The 15-Day Response Window

Each warning letter triggers a 15 business-day window in which the recipient must respond to the FDA describing corrective actions. Failure to respond, or an inadequate response, can escalate to seizure, injunction, or referral to the Department of Justice for civil or criminal action.

Based on publicly filed responses, most companies have taken one of three paths: pulling specific formulations from the market, rewriting marketing copy to add FDA disclaimers, or winding down compounded GLP-1 operations entirely and transitioning patients to brand-name prescriptions.

What This Means for Patients

If you were receiving compounded GLP-1s from a telehealth provider, the most important question is whether your provider is still operating legally. The FDA action did not shut down all compounded GLP-1 distribution — personalized compounding for patients with documented clinical need (such as allergies to inactive ingredients in brand-name formulations) remains permissible under 503A rules. What is no longer permissible is mass-production of essentially-copy compounded medications now that the shortages are resolved.

The Regulatory Arc, 2023–2026

For a broader look at where legitimate compounded access still exists, see our investigation on which compounding pharmacies are still operating and our fact check on compounded tirzepatide's current legal status.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, pricing data, or provider selection.